clinical management. The studies have a much lower radiation dose than an IVU by a factor of between 4 and 10 times. The part that isotope studiesplayin the diagnosis of uretericobstruction as opposed to' hydronephrosis has yet to be determined.
Urography withscreening anddiuresis:In borderline cases urographic signs are notoriously unreliable, and such factors as whether the ureter fills well or shows adequate peristalsis bear little relationship to the presenceor absenceofobstruction. However, the renal pelvis undoubtedly can increase in size considerably during a urogram, particularly after the administration of a diuretic, and this can be a useful guide to the presenceof obstruction (Whitfield et 01. 1979) . The method inevitably has its limitationsand shouldbeconsidered togetherwith other methods whenassessing obstruction.
There emerged from this stimulating meeting the feeling that there are problemcases that need considerablethought and diagnosticacumen. The diagnostic approach must be broad, and full collaborationisessential between the urologist, the
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A discussion on the testingof new medicines, held in December 1979, was chaired by Sir John Butterfield. In his introduction. the chairman regretted the very widespread ignorance amongst practising doctors about the test requirements during the development of new medicines. This wasunfortunate,as the current trendof regulations in the UK was producinga vicious circle that not Iilnly threatened the further advances in medical therapeutics which doctors had come to expect, but also clinical pharmacology as a profession in Britain,bccauscsomanytrialswerenowconducted overseas, The latter would have a significantly deleteriouseffect on the training of doctors in the future.
Sir John recognized that, on grounds of safety, regulatory authorities inevitably tried to legislate foralleventualities. Evenso. wewerenot prepared for the surprises which were likely 10 come with major new therapeutic advances. It was just as impossible to cover all eventualities as it was to I Reportora meetingheldb)'the Medico-Pharmaceutical forum, I Wimpolc Street, London WIM SAE, on 5 December 1979 0141-0768180/050379·02/$0 1.00/0 radiologist, and the specialistin nuclearmedicine. There needs to be a continuing evaluation of the various methods that have been discussed in the hopethat wecan find a fully reliableand preferably noninvasivetechnique. ROBERT have a new medicinewith absolutesafety,and Sir John delved into his classical background to say that, in order to break the vicious circle, our leaders needed the old virtues of 'Knowledge, Justice, Courageand a senseof Style'(Bowra), Dr Paul Bayliss (lCI) describedthe work which had to be carried out in the UK before a new medicine could be tested in patients, and showed that it differed little from that required by other countries for a marketing licence, A balance was always needed between the search for absolute safetyand the encouragement of new drug development. but the UK appeared to be leaning away from the development of new medicines, with a consequential risk to clinical pharmacology, innovative pharmaceutical research and patient benefit.
An analysis from ICI showed that only about 3%of researchworkwasproductive.largely due to the extensive tests conducted on compounds that were later abandoned at the early clinical testing stage.Theonlywaytoincreaseproductiveresearch work wasto obtain an earlier clinicaldecision, but the time and work before clinical testing in the UK WIIS, on average, over four times that needed in Germany, HoIland, Sweden and the USA.
It wassuggested that muchof the animaltoxicity and chemistry and pharmacy requirements were inappropriate, and that the formal regulations in the UK were driving clinical work on potential new medicines out of the country. This had to be viewed against the general background for the industry, where the high risks and the short effective patent life of about ten years from marketing werestrongdisincentives to innovative research.
Dr· Bayliss ended on a hopeful note, as there wererumoursthat changesmight take placein the UK. He recommended a system similar to that in Germany with guidelines for appropriate tests, whichshouldbesummarized and submittedbefore clinical testing, without the formal approvals that currently took ten times as long in the UK as compared to the other countriesreviewed.
Professor Colin Dollery (Royal Postgraduate Medical School) looked at the problem from the viewpoint of a clinical pharmacologist. He accepted the need for regulation of the marketingof medicines but questioned the need for close regulation of clinical trials, particularly in their early stages. Experience had shown that the risks of early and well supervised clinical testing were small compared to those when a medicine descends from the scientific temple into the market place' and regulations should be directed to the greater rather than the lesser risk -a state which currentlydid not apply in the UK.
The work required before clinical trials were allowed in the UK was almost as great as that needed for marketing and its scrutiny was needlessly long. Fortunately for the pharmaceutical industry there were other countries with less protracted systems and early studies of new medicines discovered in the UK or elsewhere were now rarely done in Britain, a situation which was disadvantageous to everyone in Britain, whether patients, practitioners,academics or industrialists.
Any system introduced must apply equally to smaIland largecompaniesand to experienced and inexperienced investigators, and must also recognize that some investigators and most ethics committees found it very difficult to interpret animal studies.
In the end, Professor Dollery felt that some regulation of clinical trials was required but with a system whichreduced thecurrent barriersagainst early trials in the UK. He would prefer to see summaries of data lodged with the secretariat of the Committeeon Safetyof Medicines (CSM)and cleared rapidly, but recognized the added responsibility which the secretariat would have to take. If this was unacceptable, then some form of exemption procedure for early clinical trials was the most likely way in which the government would moveto reducethe delaysoperatingagainst clinical pharmacology and the innovative pharmaceutical industry in the UK.
Drawing conclusions from the two papers, Sir John Butterfield, who is also chairman of the Medicines Commission, felt that the Medico-Pharmaceutical Forum had performed a most useful function in highlighting joint problems facing the profession and the industry. There was need to use flexible procedures and voluntary systems rather than resorting always to legislation.'
The warnings given in these papers should be widely publicized; otherwise we would be losing our active clinical pharmacologists and our successful innovative pharmaceutical research.
In a lively discussion chaired by Dr T J Thomson, chairman of the Medico-Pharmaceutical Forum,it wasestablishedthat over80% of new medicines discovered in the UK wentoverseas for clinicaltesting,witha tendency forpharmaceutical research and production to follow.
Although talks had been held with the UK Licensing Authority for seven years without any action, there now appeared hopeof improvement and the system preferred by the meeting was the submission with the CSM of a twenty-page summary and a two-page description of the trial protocol on the understandingthat trials would be aIlowed to start if no objections were raised within thirty days. For the system to work, objections would be exceptional and open to appeal via.the committees. Suchchangeswereallowed withinthe Medicines Act but the CSM secretariat were the key people who would have to take the responsibility if we were to get out of the present longwinded, rigid system and nearer to the more flexible daysof the Committeeon Safetyof Drugs.
The suggested system of 'summaries to CSM secretariat for carly clinical trials' had the support of the colleges represented, whilethe alternativeof 'giving exemption to certain trialists' could introduce a different bottle-neck and limit the more generalexperienceof experimental therapeuticsin the profession.
A change to a simplified clinical trial system shouldencourageclinical pharmacology but there would be needfor trainingof doctorsgenerally and possibly of ethics committees, who might take a more active role in the follow up of allowed trials.
The meeting ended with the hope that the rumours of change were correct and that years of talking with no action except increasing regulationsand delayswould nowbe followed bydecisive moves to encourage the testing of new medicines in the UK, thus bringing it into line with the majorityof its European partners.
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